Polaryx Therapeutics, Inc. balance sheet PLYX

As of Jun 30, 2026, Polaryx Therapeutics, Inc. had total assets of $11.8 million and total liabilities of $873,000. Stockholders' equity was $10.9 million. Cash and investments were $11.5 million. The current ratio, current assets divided by current liabilities, was 13.53.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Assets
Cash
12
3
5
Cash and investments
12
3
5
Total current assets
12
4
5
Total assets
12
4
5
Liabilities and equity
Accounts payable
1
1
0
Total current liabilities
1
1
1
Total liabilities
1
1
1
Stockholders' equity
11
2
5
Ratios
Current ratio
13.53x
3.45x
8.55x
Return on equity
—
—
-196.82%
Return on assets
—
—
-173.79%
Book value per share
0.22
0.05
0.10
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PLYX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
WY
Headquarters
Paramus, NJ
SEC filer status
, Emerging growth company
SEC CIK
2075320

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.